Abstract:Khaldoun Almhanna Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, USA Comment on: Kelley RK, Ueno M, Yoo C, et al . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-65. Erratum in: Lancet 2023;402:964. Keywords: Biliary cancer; TOPAZ-1; KEYNOTE-966 Submitted Sep 23, 2023. Accepted for publication Dec 07, 2023. Published online Jan 17, 2024. doi: 10.21037/tcr-23-1763 Biliary malignancies are rare but fatal diseases with rising incidence worldwide. Patients often present with unresectable or metastatic disease; even when presenting early, the disease has a high recurrence rate with overall poor prognosis (1). Gemcitabine and cisplatin combination has been established as the standard of care for metastatic disease for more than two decades since the completion of the ABC-02 trial. The trial randomized 401 patients with locally advanced or metastatic disease to receive either gemcitabine alone or in combination with cisplatin. Patients who received the combination had a better overall survival (OS) (11.7 months in the combination arm vs. 8.1 months in the single agent gemcitabine arm, P<0.001) compared to those who received gemcitabine alone (2). Since then, several combinations failed to improve the outcome in metastatic biliary cancer. Finding more effective treatment has been challenging especially with the rarity and heterogeneity of the disease, and the poor liver function at presentation. Recently two large randomized trials evaluated the addition of immune checkpoint inhibitors (ICI) to standard chemotherapy in patients with advanced biliary cancer: In the TOPAZ-1 trial, 685 patients with advanced biliary cancer were randomized to receive gemcitabine and cisplatin with durvalumab, a programmed death cell ligand 1 (PD-L1) inhibitor, or placebo, followed by maintenance durvalumab in the intervention arm. The trial showed statistically significant improvement in OS favoring the addition of durvalumab (12.8 vs. 11.5 months, hazard ratio, 0.80; 95% CI: 0.66 to 0.97; P=0.021). An improvement in progression-free survival (PFS) and objective response rate (ORR) was noted as well. Toxicities were similar between the two arms (3). More recently, the addition of another programmed cell death protein 1 (PD-1) targeted agent, pembrolizumab, to gemcitabine and cisplatin was evaluated in another phase III double blind-placebo control trial: KEYNOTE-966. A total of 1,069 newly diagnosed biliary cancer patients were randomized to receive either pembrolizumab or placebo in combination with chemotherapy for a total of 8 cycles or best response followed by maintenance gemcitabine plus either placebo or pembrolizumab. At median follow-up of 26 months, the addition of pembrolizumab led to a statistically significant improvement in OS (12.7 vs. 10.9 months, hazard ratio =0.83, P=0.0034) and PFS (6.5 vs. 5.6 months, P=0.023). Response rate was similar in both arms but with higher duration of response in the intervention arm. Survival benefits were seen across all biliary cancer subgroups, including intra/extra hepatic cholangiocarcinoma (4). Adding pembrolizumab did not significantly increase toxicity compared to placebo. Health-related quality of life (HRQoL) was maintained with the addition of pembrolizumab (5). In both trials, the incidences of significant adverse events were similar between the two treatment groups; of interest, In the TOPAZ-1 trial, the rate of immune-mediated adverse events was 12.7% with durvalumab and 4.7% with placebo. Grade 3 or 4 immune-mediated adverse events occurred in 2.4% of patients in the durvalumab group and 1.5% in the placebo group. In the KEYNOTE-966 study, immune-mediated adverse events of any grade occurred in 22% of the experimental arm versus13% of the control arm. Grade 3 and 4 immune-related adverse event occurred in 7% and 4% respectively. Both, the TOPAZ-1 and KEYNOTE-966 trials confirm the modest role of adding immune check point inhibition to chemotherapy in the treatment of unresectable and metastatic biliary tumors making it a new standard of care. Benefits were seen irrespective of age, sex, geographic region, tumor location or PD-L1 combined positive score (CPS). Looking closer, KEYNOTE-966 differs from TOPAZ-1 in that it allowed continuing Gemcitabine alone or in combination with PD-1 inhibitor after eight cycles, so patients were exposed to chemotherapy longer, while in the TOPAZ-1 trial, patients were continued on durvalumab alone in the intervention arm. There were also small differences in the subgroup of patients enrolled in both trials; in the -Abstract Truncated-

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Nivolumab in Combination with Gemcitabine and Cisplatin for Advanced Unresectable or Metastatic Biliary Tract Cancers: Results from a Single Center, Single-Arm, Phase I Study

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer

Lenvatinib plus PD-1 inhibitors combined with chemotherapy versus lenvatinib plus PD-1 inhibitors for unresectable or recurrent biliary tract cancer

Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

Lenvatinib Plus PD-1 Blockade in Refractory or Unresectable Biliary Tract Carcinoma: Insights from Real-World Evidences

AB052. P-20. Phase 2, Open-Label Study of Second-Line M7824 Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancer

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study